EIM
AUTL

Essex Investment Management’s Autolus Therapeutics AUTL Stock Holding History

Essex Investment Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-80,138
Closed -$2.46M – 482
2018
Q3 		$2.46M Buy
80,138
+42,396
+112% +$1.14M 0.29% 95
2018
Q2 		$1.01M Buy
+37,742
New +$997K 0.13% 221

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Essex Investment Management's AUTL Position: Q4 2018 in Review

Essex Investment Management sold out of Autolus Therapeutics (AUTL) in Q4 2018, closing a stake of 80,138 shares — an estimated $2.46M sold.

Essex Investment Management first reported a position in AUTL in Q2 2018 and held it in 2 quarters. The position peaked at $2.46M in Q3 2018. 38 funds tracked by Wall St. Rank hold AUTL as of Q4 2018.

  • Essex Investment Management reported no remaining Autolus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 80,138 Autolus Therapeutics shares in Q4 2018, an estimated $2.46M.
  • Essex Investment Management first reported a position in Autolus Therapeutics in Q2 2018 and held it in 2 quarters.
  • Essex Investment Management's Autolus Therapeutics position peaked at $2.46M in Q3 2018.
  • 38 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.